Design Design of de novo designed molecules at the Peroxisome Proliferator Activated Receptor
- At: 2013 FIP Congress in Dublin (Ireland)
- Type: Poster
- By: SHOEMAKE, Claire (University of Malta, Pharmacy, Msida, Malta)
- Co-author(s): Portelli, Stephanie (University of Malta, Msida, Malta)
Azzopardi, Lilian (University of Malta, Msida, Malta)
Rosiglitazone withdrawal from the markethas led to a renewed interest in the Peroxisome Proliferator Activated Receptor Ã£ (PPARÃ£) as target for type 2 diabetes therapies, mainly via partial agonism. This may be achieved via selective PPARÃ£ modulators such as S-26948.
To obtain and optimise molecules having a high affinity to PPARÃ£ The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.